investigators – Page 10 – Communicable Diseases Research

Efficacy and safety of Anluohuaxian in the treatment of patients with severe Coronavirus disease 2019- a multicenter, open label, randomized controlled study: a structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-06-082022-10-29
Journal: Trials [Category] Coronavirus, SARS,

The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-06-052022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 24 hours acid Administered Affect analyst Anti-viral anticipated Beijing block block randomization Blood Body Capital cardiovascular system Care center changed Chinese clinical clinical manifestation Clinical outcome Clinical studies clinical trial college Complete condition Consent control group Corona Corona virus cough COVID-19 criteria curative Diagnosis discharge discharged disease Diseases dissemination dose drug Ebola virus element eligibility criteria enrolled expected experimental group Favipiravir female Follow-up form hepatology history hospital include Including Infection Infectious disease Informed inhibit investigators kidney lack lactating women life-threatening liver Loss male Measures mechanism Medicine Mental Disorders Nasopharyngeal swab nasopharyngeal swabs not blinded nucleic acid nucleic acid test number objective open label oral administration outcome outcome assessors Oxygen therapy parallel group participant Participants Patient plan poor compliance positive protocol Public pulmonary randomised randomised controlled trial randomization system Randomized controlled trial Randomly recruited recruitment reduced Regular Reinfection Research researcher respiratory specimen response returned RNA-dependent RNA polymerase routine screening visit second secondary severe adverse events severity severity of symptoms Shenzhen specimens sputum status Study protocol subject Symptom Symptoms System temperature Test tested therapeutic efficacy throat swabs Traditional Treatment treatment for COVID-19 treatment group Trial uncontrolled university variety viral nucleic acid virus Web website Withdrawal Wuhan
[DOI] 10.1186/s13063-020-04430-y PMC 바로가기 [Article Type] Letter

Two Randomized Controlled Trials of Bacillus Calmette-Guérin Vaccination to reduce absenteeism among health care workers and hospital admission by elderly persons during the COVID-19 pandemic: A structured summary of the study protocols for two randomised controlled trials

Letter

Published on 2020-06-052022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 ambulance service assistant Bacillus BCG BCG vaccination BCG-vaccine blinded Care Community Controlled COVID-19 COVID-19 infection COVID-19 pandemic cumulative Denmark dissemination elderly element facilitate HCW HCWs Health care Health care worker Health-care workers hospital Hospital admission hospitals incidence Intervention intervention group investigators Medicine NaCl Netherlands number objective outcome outcome assessor parallel group participant Patient physician Placebo placebo group placebo-controlled protocol randomised randomised controlled trial Randomized randomized trial recruitment reduce Registered registry Research Sample size status stratified Study protocol the placebo group Trial vaccination Vaccine website
[DOI] 10.1186/s13063-020-04389-w PMC 바로가기 [Article Type] Letter

A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-06-032022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 48 hour Admission allergic reaction anticipated application AST/ALT Bacterial infection Bacterial infections blinded block Breast feeding clinical clinical trial Combination concealed conducted Contraception Control COVID-19 COVID-19 patient criteria defined dependent on Desirable diagnostic Diaphragm dissemination dose double blind ECMO Efficacy Efficacy and safety element Endpoint evaluate extracorporeal membrane oxygenation failure female Germany Hospital stay Hydroxychloroquine IL-6-Rezeptor blockade Immunosuppression immunosuppressive therapy IMV independent Inflammation ingredient Injury Inpatient intensive care units interfere Invasive mechanical ventilation investigator investigators less life lung failure mechanical ventilation methotrexate NaCl NIV non-invasive ventilation number objective outcome parallel group parameters participant Participation Pathogenesis Patient patients PCT performed placebo-controlled trial Pneumonia polymerase chain positive Prednisolone produced progression proof protocol Pulmonary function pulmonary inflammation Quality of life randomisation randomised randomised controlled trial recruited reduce Registered respiratory Safe Sample size SARS-CoV-2 SARS-CoV2 SARS-CoV2 infection SAS severe COVID-19 Severe COVID-19 pneumonia Simultaneous single dose status stratified Study protocol sulfasalazine System the patient therapy Tocilizumab Treatment Trial trials Tuberculosis ULN unit Ventilation ventilator ventilator free day ventilator free days VFD Viral hepatitis website
[DOI] 10.1186/s13063-020-04447-3 PMC 바로가기 [Article Type] Letter

A short, animated video to improve good COVID-19 hygiene practices: a structured summary of a study protocol for a randomized controlled trial

Letter

Published on 2020-06-032022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 age Algorithm anonymously APC Arm avoidance Behavioral intent behavioural blinded changes in clinical component control arm control group country COVID-19 COVID-19 outbreak Developed dissemination Effect Effectiveness Effects element eligible English Entertainment-education excluded expected experiment Face masks female FIVE France French Germany Gorilla highest Host hygiene IMPROVE include Interaction Intervention intervention arm investigator investigators item knowledge List experiment male media Medicine Novel coronavirus number objective outcome outcome measure parallel group participant Participants physical contact Placebo platform Prevalence Prevent Primary outcome Prolific Academic protocol question questionnaire randomised controlled trial randomization randomize Randomized Randomized controlled trial Randomly RCT reached receive recruit recruited reduce Registered secondary outcome sequence Sex social distancing Spain Spanish Spread spread of COVID-19 Stanford Study protocol submitted The United States total sample size Treatment treatment group Trial United Kingdom was collected washing hand washing hands website
[DOI] 10.1186/s13063-020-04449-1 PMC 바로가기 [Article Type] Letter

Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China

Opinion Article

Published on 2020-02-072022-10-31
Journal: F1000Research [Category] COVID-19, MERS, SARS,

[키워드] 2019-nCoV 2019-nCoV infection ACE2 ACE2-Fc acute respiratory distress angiotensin-converting enzyme 2 approaches biologic block breath build clinical trial compassionate use coronavirus current death develop domain effective therapy effort fused help helping immune system Immunity Immunoglobulin infected individuals infected patient Infection investigators lung mechanism of action monoclonal antibody Mutation Neutralizing neutralizing antibody Novel coronavirus outbreak pandemic pathophysiology Patient patients Prevent producing Protective Protein protein expression provided quarantine receptor recruit Research respiratory viral sequence therapy treat Treatment Vaccine viral escape viral RNA genome virus while Wuhan Wuhan, China
[DOI] 10.12688/f1000research.22211.2 PMC 바로가기 [Article Type] Opinion Article

Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial

저위험 HIV 감염되지 않은 남아프리카 성인을 대상으로 한 아형 C ALVAC-HIV 및 2가 아형 C gp120/MF59 HIV-1 백신: 1/2상 시험

Article

Published on 2018-06-182022-09-06
Journal: The Lancet. HIV [Category] Communicable Disease,

[키워드] 95% CI added adjuvant advancement African allergy Antigen assigned binding antibody CD4+ T-cell changed circulating clinical Community component computer-generated Critical double-blind trial Efficacy enrolled exceeded Express finding foundation funding glycoprotein gp120 HIV HIV infection HIV vaccine HIV-1 HIV-uninfected IgG IgG response immune response immune responses immunogenicity IMPROVE Infectious disease Infectious diseases Intramuscular injection investigators Melinda Gate Melinda Gates MF59 network NIAID outcome participant per-protocol per-protocol analysis Placebo predicted Primary outcomes Protein provided random randomisation randomised controlled Randomly recipient regimen Registered registry reported Research responders response risk significantly higher South South Africa strain Strains subtype T-cell Response tested the vaccine threshold titre Trial vaccination Vaccine Vaccine development was done
[DOI] 10.1016/S2352-3018(18)30071-7 PMC 바로가기 [Article Type] Article

Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial

HIV-1에 감염된 건강한 성인에서 후보 결핵 백신 MVA85A의 안전성, 면역원성 및 효능: 무작위, 위약 대조, 2상 시험

Articles

Published on 2015-03-012022-09-06
Journal: The Lancet. Respiratory Medicine [Category] Communicable Disease,

[키워드] 1:1 95% CI absence active tuberculosis adverse event Antigen antigen 85A antigen 85A-specific T-cell response antiretroviral Antiretroviral therapy assigned assist baseline baseline CD4 block blocks booster Cape CD4 count CD4 counts Cell clinical defined detect detectable Developing disease double-blind effective Efficacy eligible Eligible participants enrolled enrolment European Evidence evidence of expressing finding first vaccination foundation funding gold greater Group allocation had no healthy HIV-1 HIV-1 infection immunogenic immunogenicity include increased risk Infection injection intradermal injections investigators isoniazid isoniazid prophylaxis Laboratory latent tuberculosis latent tuberculosis infection M tuberculosis Measures Melinda Gate Melinda Gates modified vaccinia virus MVA85A Mycobacterium tuberculosis nine no evidence of Nurses occurred outcome participant partnership peaked per-protocol analysis per-protocol population Phase 2 phase 2 trial Placebo placebo group placebo-controlled positive Potential Prophylaxis protocol QuantiFERON QuantiFERON-TB Gold In-Tube randomisation randomised Randomly receive receiving Registered reported Safe Safety safety analysis second vaccination secondary Secondary outcomes sequence Serious Adverse Event Serious Adverse Events significant increase South Africa stratified subset T-cell Response the placebo group therapy town Treatment Trial Tuberculosis tuberculosis disease tuberculosis vaccine undetectable vaccination Vaccine vaccine efficacy vaccine-induced immune response Viral Viral load Wellcome Trust were assessed
[DOI] 10.1016/S2213-2600(15)00037-5 PMC 바로가기 [Article Type] Articles

Combining Quantitative Genetic Footprinting and Trait Enrichment Analysis to Identify Fitness Determinants of a Bacterial Pathogen

정량적 유전 발자국과 특성 강화 분석을 결합하여 세균성 병원체의 적합성 결정 요인 식별

Research Article

Published on 2013-08-222022-09-06
Journal: PLoS Genetics [Category] Communicable Disease,

[키워드] a major abundance Affect Algorithm Antibiotic resistance approach approaches array assortment Author Bacterial bacterial gene bacterial genes benefit bioinformatics candidate gene changes in Combination conjunction conserved dataset deep sequencing deleted determinant determinants Determining diagnostic dissect Diversity DNA binding E. coli effective effort enrichment Escherichia Escherichia coli Factor fitness Follow-up analysis Footprinting found Gene Genes Genetic Genome genomes highest highlight homologue homologues Host hypothetical identify increasingly independent Infection infections insertion investigator investigators isolates Meningitis molecular mouse model Mutagenesis mutant novel observation observations pathogen Pathogenesis pathogenic pathogenic strain pathogenic strains Pathogens phenotypic phenotypic variation phylogenetic distribution promote Quantitative reported required Research resource saturated Sepsis Sequencing shown strain Strains suggested therapeutic therapeutic targets Therapies Tn-seq to define trait transcriptional repressor transposon urinary tract infections variant Variation virulence virulence gene widespread zebrafish
[DOI] 10.1371/journal.pgen.1003716 PMC 바로가기 [Article Type] Research Article

A Genome-Wide Meta-Analysis of Six Type 1 Diabetes Cohorts Identifies Multiple Associated Loci

6개의 1형 당뇨병 코호트에 대한 게놈 전체 메타 분석으로 여러 관련 유전자좌 식별

Research Article

Published on 2011-09-292022-09-06
Journal: PLoS Genetics [Category] Communicable Disease,

[키워드] ADCY3 affected association Author C6orf120 CENPO chromosomal combined cohort contributing to controls dataset diabete diabetes disease DLL1 DNAJC27 DNMT3A domain EFR3B examined excess FAM120B Follow-up Gene gene network gene networks Genes Genetic genetic component genetic loci genetic screening Genome Genome-wide association studies Genome-wide association study genome-wide significance genotyped GWAS homolog hypotheses identify Impact independent intergenic region intronic region investigator investigators Linkage disequilibrium LMO7 LOC154449 loci meta-analyses Meta-analysis Multiple NCOA1 Pathogenesis PHF10 POMC Protein PSMB1 reached recent finding Region replicated risk risk for disease significantly SNP SNPs susceptibility T1D TBP the disease Type Type 1 diabetes variant variants WDR27
[DOI] 10.1371/journal.pgen.1002293 PMC 바로가기 [Article Type] Research Article